CN115297893B - 用于在体内寻址α-v-β-6-整合素的环肽及其缀合物 - Google Patents

用于在体内寻址α-v-β-6-整合素的环肽及其缀合物

Info

Publication number
CN115297893B
CN115297893B CN202180020982.9A CN202180020982A CN115297893B CN 115297893 B CN115297893 B CN 115297893B CN 202180020982 A CN202180020982 A CN 202180020982A CN 115297893 B CN115297893 B CN 115297893B
Authority
CN
China
Prior art keywords
group
conjugate
pharmaceutically acceptable
acceptable salt
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180020982.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN115297893A (zh
Inventor
约翰内斯·诺特尼
尼尔·奎格利
卡佳·斯泰格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technical University of Munich
Original Assignee
Technical University of Munich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technical University of Munich filed Critical Technical University of Munich
Publication of CN115297893A publication Critical patent/CN115297893A/zh
Application granted granted Critical
Publication of CN115297893B publication Critical patent/CN115297893B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
CN202180020982.9A 2020-03-12 2021-03-12 用于在体内寻址α-v-β-6-整合素的环肽及其缀合物 Active CN115297893B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20162699.1 2020-03-12
EP20162699 2020-03-12
PCT/EP2021/056424 WO2021180969A1 (en) 2020-03-12 2021-03-12 Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo

Publications (2)

Publication Number Publication Date
CN115297893A CN115297893A (zh) 2022-11-04
CN115297893B true CN115297893B (zh) 2025-09-23

Family

ID=69810651

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180020982.9A Active CN115297893B (zh) 2020-03-12 2021-03-12 用于在体内寻址α-v-β-6-整合素的环肽及其缀合物

Country Status (11)

Country Link
US (1) US20230173113A1 (cg-RX-API-DMAC7.html)
EP (1) EP4117736A1 (cg-RX-API-DMAC7.html)
JP (1) JP7787083B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220152322A (cg-RX-API-DMAC7.html)
CN (1) CN115297893B (cg-RX-API-DMAC7.html)
AU (1) AU2021233176A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016986A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175061A1 (cg-RX-API-DMAC7.html)
IL (1) IL296081A (cg-RX-API-DMAC7.html)
MX (1) MX2022011287A (cg-RX-API-DMAC7.html)
WO (1) WO2021180969A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226432A2 (en) * 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections
CN120829485A (zh) * 2024-04-16 2025-10-24 中山医诺维申新药研发有限公司 双重靶向成纤维细胞激活蛋白和整合素亚型的化合物及其制备和应用
WO2026027771A1 (en) 2024-08-02 2026-02-05 Trimt Gmbh Alpha v beta 6-integrin binding cyclopeptides with non-natural amino acids, and conjugates thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137694A (zh) * 2015-09-18 2018-06-08 慕尼黑工业大学 整合素αvβ6的配体及其合成和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19933173A1 (de) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
WO2009117531A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
EP3107557B1 (en) 2014-02-17 2021-06-09 Seagen Inc. Hydrophilic antibody-drug conjugates
CN109563135B (zh) * 2016-06-13 2024-01-23 加利福尼亚大学董事会 α(V)β(6)整合素结合肽及其使用方法
WO2019154842A1 (en) * 2018-02-06 2019-08-15 Klinikum Rechts Der Isar Der Technischen Universität München Compound for intraoperative molecular bioimaging, method of making the same, use thereof in intraoperative molecular bioimaging and surgical method comprising intraoperative molecular bioimaging

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137694A (zh) * 2015-09-18 2018-06-08 慕尼黑工业大学 整合素αvβ6的配体及其合成和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Stable Peptides Instead of Stapled Peptides: Highly Potent avb6- Selective Integrin Ligands;Oleg V. Maltsev等;Angew. Chem. Int. Ed.;20161231;第1535-1539页 *

Also Published As

Publication number Publication date
KR20220152322A (ko) 2022-11-15
CN115297893A (zh) 2022-11-04
US20230173113A1 (en) 2023-06-08
WO2021180969A1 (en) 2021-09-16
AU2021233176A1 (en) 2022-09-08
IL296081A (en) 2022-11-01
JP7787083B2 (ja) 2025-12-16
EP4117736A1 (en) 2023-01-18
BR112022016986A2 (pt) 2022-10-25
CA3175061A1 (en) 2021-09-16
JP2023518161A (ja) 2023-04-28
MX2022011287A (es) 2022-12-08

Similar Documents

Publication Publication Date Title
KR100932827B1 (ko) 펩티드계 화합물
Poschenrieder et al. The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity
Medina et al. Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide
BRPI0909823B1 (pt) Conjugados antagonistas de peptídeo análogo de bombesina, seu uso e seu processo de preparação, composição farmacêutica, processo para formação de imagem de receptores de bombesina e kit
US8986651B2 (en) Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
EP1991562A2 (en) Cancer imaging and treatment
CA2413538A1 (en) Stable radiopharmaceutical compositions and methods for preparation thereof
BR112015006453B1 (pt) Antagonista de grpr radiomarcado e composição terapêutica que o compreende
JP7787083B2 (ja) アルファ-v-ベータ-6-インテグリンをインビボでアドレッシングするための環状ペプチド及びそれらのコンジュゲート
Ma et al. Gallium-68 complex of a macrobicyclic cage amine chelator tethered to two integrin-targeting peptides for diagnostic tumor imaging
Müller et al. Single photon emission computed tomography tracer
US11141494B2 (en) Development of neurokinin-1 receptor-binding agent delivery conjugates
US6517814B2 (en) Macrocyclic chelants useful for metallopharmaceuticals
Echigo et al. Development and evaluation of a theranostic probe with RGD peptide introduced platinum complex to enable tumor-specific accumulation
Turnbull et al. A dual modality 99mTc/Re (I)-labelled T140 analogue for imaging of CXCR4 expression
DK2795317T3 (en) Composition for use in a cancer selection method
CA3119793A1 (en) Radiopharmaceuticals and methods of use thereof
AU2005254915B2 (en) Peptide-based compounds
KR20250016195A (ko) 전립선-특이적 막 항원(psma) 리간드
Papagiannopoulou 99mTc Radiopharmaceutical chemistry
KR101551232B1 (ko) N3s1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물
WO2002055112A2 (en) Polypodal chelants for metallopharmaceuticals
EP4455159A1 (en) Gastric inhibitory peptide receptor ligands with bio-distribution modifier
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
WO2005110497A1 (en) Imaging of tumors and metastases using a gelatinase targeting peptide comprising the structure ctthwgftlc.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant